Eli Lilly & CO Form 4 insider transactions

EVP, GC & Secretary of Eli Lilly, Anat Hakim, reports transferring shares to a spousal lifetime access trust and to her spouse on May 2, 2025.

Director Gabrielle Sulzberger acquired 6.061 shares of Eli Lilly & Co. common stock under the company's Directors' Deferral Plan.

Director Juan R. Luciano acquired 18.133 shares of Eli Lilly & Co common stock under the company's Directors' Deferral Plan.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired shares of common stock under the Lilly Directors' Deferral Plan.

Director J. Erik Fyrwald acquired 12.123 shares of Eli Lilly & Co common stock at $818.02 per share under the Lilly Directors' Deferral Plan.

Director Ralph Alvarez acquired 14.364 shares of Eli Lilly & Co common stock at $818.02 per share under the Lilly Directors' Deferral Plan.

Director Gabrielle Sulzberger acquired 6.012 shares of Eli Lilly & Co common stock on March 17, 2025, through the Lilly Directors' Deferral Plan.

Director Juan R. Luciano acquired 17.985 shares of Eli Lilly & Co common stock at $824.76 per share on March 17, 2025, under the company's Directors' Deferral Plan.

Mary Lynne Hedley, a director of Eli Lilly & Co, acquired 12.024 shares of common stock at $824.76 per share through the Lilly Directors' Deferral Plan.

Director J. Erik Fyrwald acquired 12.024 shares of Eli Lilly & Co common stock at $824.76 per share under the company's Directors' Deferral Plan.

Director Ralph Alvarez acquired 14.246 shares of Eli Lilly & Co common stock under the Lilly Directors' Deferral Plan.

Donald Zakrowski, SVP of Finance & CAO at Eli Lilly & Co, sold 1,000 shares of common stock at $818.24 per share on March 13, 2025, under a pre-arranged 10b5-1 trading plan.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., sold a significant portion of its holdings on March 3, 2025, reducing its position by approximately $162 million.

Eric Dozier, EVP and Chief People Officer at Eli Lilly, executed restricted stock units and disposed of shares to cover tax obligations.

EVP & Pres., Mfg. Operations Edgardo Hernandez reports acquisition and disposal of Eli Lilly & Co stock and restricted stock units on March 1, 2025.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., has sold a significant portion of its holdings in multiple transactions on February 25, 2025.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, reports selling shares in multiple transactions on February 24, 2025.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co, reports the sale of a portion of its common stock holdings on February 21, 2025.

Eric Dozier, EVP and Chief People Officer at Eli Lilly & Co, reported a gift of 460 common stock shares and updates to derivative security holdings.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., executed multiple sales of common stock on February 20, 2025.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., executed multiple sales of common stock on February 19, 2025, at weighted average prices ranging from $877.373 to $880.443.

Director Gabrielle Sulzberger acquired 5.784 shares of Eli Lilly & Co common stock at $857.2 per share through the Lilly Directors' Deferral Plan.

Director Juan R. Luciano acquired 17.304 shares of Eli Lilly & Co common stock on February 18, 2025, under the company's Directors' Deferral Plan.

Director Mary Lynne Hedley acquired 11.569 shares of Eli Lilly & Co (LLY) common stock at $857.2 per share through the Lilly Directors' Deferral Plan.

Director J Erik Fyrwald acquired 11.569 shares of Eli Lilly & Co common stock at $857.2 per share on February 18, 2025, under the Lilly Directors' Deferral Plan.

Director Ralph Alvarez acquired 13.708 shares of Eli Lilly common stock through the Lilly Directors' Deferral Plan, deferring cash compensation into stock units.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, reports selling shares in multiple transactions on February 13, 2025.

EVP & President of Eli Lilly International, Ilya Yuffa, reports acquisition and disposal of common stock and acquisition of restricted stock units.

EVP & President of Lilly Neuroscience, Anne E. White, reports acquiring common stock and restricted stock units of Eli Lilly & Co.

EVP & President of Lilly Oncology, Jacob Van Naarden, reports acquisition and disposal of Eli Lilly & Co. common stock and restricted stock units.